240 related articles for article (PubMed ID: 25871400)
1. Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation.
Zhou Y; Liang C; Xue F; Chen W; Zhi X; Feng X; Bai X; Liang T
Oncotarget; 2015 Apr; 6(12):10350-65. PubMed ID: 25871400
[TBL] [Abstract][Full Text] [Related]
2. Shc3 promotes hepatocellular carcinoma stemness and drug resistance by interacting with β-catenin to inhibit its ubiquitin degradation pathway.
Liu Y; Zhuang H; Cao F; Li J; Guo Y; Zhang J; Zhao Q; Liu Y
Cell Death Dis; 2021 Mar; 12(3):278. PubMed ID: 33723262
[TBL] [Abstract][Full Text] [Related]
3. Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice.
Dieudonné FX; Marion A; Marie PJ; Modrowski D
J Bone Miner Res; 2012 Oct; 27(10):2118-29. PubMed ID: 22550000
[TBL] [Abstract][Full Text] [Related]
4. FOXO3a modulates WNT/β-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells.
Liu H; Yin J; Wang H; Jiang G; Deng M; Zhang G; Bu X; Cai S; Du J; He Z
Cell Signal; 2015 Mar; 27(3):510-8. PubMed ID: 25578861
[TBL] [Abstract][Full Text] [Related]
5. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T
Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422
[TBL] [Abstract][Full Text] [Related]
6. Inter-regulation of IGFBP1 and FOXO3a unveils novel mechanism in ursolic acid-inhibited growth of hepatocellular carcinoma cells.
Yang LJ; Tang Q; Wu J; Chen Y; Zheng F; Dai Z; Hann SS
J Exp Clin Cancer Res; 2016 Mar; 35():59. PubMed ID: 27036874
[TBL] [Abstract][Full Text] [Related]
7. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo.
Wei W; Chua MS; Grepper S; So S
Int J Cancer; 2010 May; 126(10):2426-36. PubMed ID: 19662654
[TBL] [Abstract][Full Text] [Related]
8. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
[TBL] [Abstract][Full Text] [Related]
9. N1-guanyl-1,7-diaminoheptane (GC7) enhances the therapeutic efficacy of doxorubicin by inhibiting activation of eukaryotic translation initiation factor 5A2 (eIF5A2) and preventing the epithelial-mesenchymal transition in hepatocellular carcinoma cells.
Lou B; Fan J; Wang K; Chen W; Zhou X; Zhang J; Lin S; Lv F; Chen Y
Exp Cell Res; 2013 Oct; 319(17):2708-17. PubMed ID: 23958463
[TBL] [Abstract][Full Text] [Related]
10. Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2.
Lim K; Han C; Dai Y; Shen M; Wu T
Mol Cancer Ther; 2009 Nov; 8(11):3046-55. PubMed ID: 19887546
[TBL] [Abstract][Full Text] [Related]
11. Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway.
Gao AM; Ke ZP; Wang JN; Yang JY; Chen SY; Chen H
Carcinogenesis; 2013 Aug; 34(8):1806-14. PubMed ID: 23563091
[TBL] [Abstract][Full Text] [Related]
12. ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition.
Xu T; Zhang J; Chen W; Pan S; Zhi X; Wen L; Zhou Y; Chen BW; Qiu J; Zhang Y; Yang Q; Feng X; Bai X; Liang T
Cancer Lett; 2016 Jul; 377(2):140-8. PubMed ID: 27126361
[TBL] [Abstract][Full Text] [Related]
13. Increase of miR-199a-5p by protoporphyrin IX, a photocatalyzer, directly inhibits E2F3, sensitizing mesenchymal tumor cells to anti-cancer agents.
Lee JM; Heo MJ; Lee CG; Yang YM; Kim SG
Oncotarget; 2015 Feb; 6(6):3918-31. PubMed ID: 25714015
[TBL] [Abstract][Full Text] [Related]
14. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
15. Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis.
Liu L; Zhu XD; Wang WQ; Shen Y; Qin Y; Ren ZG; Sun HC; Tang ZY
Clin Cancer Res; 2010 May; 16(10):2740-50. PubMed ID: 20460486
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization.
Fei M; Lu M; Wang Y; Zhao Y; He S; Gao S; Ke Q; Liu Y; Li P; Cui X; Shen A; Cheng C
Med Oncol; 2009; 26(2):178-85. PubMed ID: 18937079
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion.
Chen L; Yuan YF; Li Y; Chan TH; Zheng BJ; Huang J; Guan XY
Gut; 2011 Apr; 60(4):534-43. PubMed ID: 21068133
[TBL] [Abstract][Full Text] [Related]
18. Codelivery of salinomycin and doxorubicin using nanoliposomes for targeting both liver cancer cells and cancer stem cells.
Gong Z; Chen D; Xie F; Liu J; Zhang H; Zou H; Yu Y; Chen Y; Sun Z; Wang X; Zhang H; Zhang G; Yin C; Gao J; Zhong Y; Lu Y
Nanomedicine (Lond); 2016 Oct; 11(19):2565-2579. PubMed ID: 27647449
[TBL] [Abstract][Full Text] [Related]
19. The promotion of salinomycin delivery to hepatocellular carcinoma cells through EGFR and CD133 aptamers conjugation by PLGA nanoparticles.
Jiang J; Chen H; Yu C; Zhang Y; Chen M; Tian S; Sun C
Nanomedicine (Lond); 2015 Jul; 10(12):1863-79. PubMed ID: 26139123
[TBL] [Abstract][Full Text] [Related]
20. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
